RxDoctor Payments Data

Eleanor Hess

Family · Abingdon, VANPI 1982607099

Payments from drug & device makers

$9,086in general payments, 2019–2025

Across 522 payments — averaging $17.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AstraZeneca$864
  • Lilly USA, LLC$779
  • Johnson & Johnson$671
  • AbbVie$579
  • Pfizer$535
  • plus $5K from 35 others

What the payments were for

  • Food & beverage$8,98799%
  • Education$991%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,086 in reported general payments places this provider in the 95th percentile of 4,332 family providers in Virginia.

See all family providers in Virginia

Medicare billing

Part B allowed, 2024
$64,866
Medicare patients
177
Services billed
1,314

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban170$130,268
MounjaroTirzepatide59$62,218
JardianceEmpagliflozin68$54,262
XareltoRivaroxaban40$36,898
OzempicSemaglutide19$31,310
FarxigaDapagliflozin Propanediol29$28,776
Trelegy ElliptaFluticasone/Umeclidin/Vilanter37$24,444
LinzessLinaclotide24$22,542
TrulicityDulaglutide20$17,977
GemtesaVibegron23$15,472
Tresiba Flextouch U-200Insulin Degludec20$13,894
Breo ElliptaFluticasone/Vilanterol19$9,944
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog15$8,125
BelsomraSuvorexant11$4,907
Omeprazole207$4,418

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$535$130,268170 claims
Lilly USA, LLCMounjaro, Trulicity$779$80,19579 claims
Boehringer IngelheimJardiance$433$54,26268 claims
Johnson & JohnsonXarelto$671$36,89840 claims
GSKTrelegy Ellipta, Breo Ellipta$368$34,38856 claims
Novo NordiskOzempic$1,049$31,31019 claims
AstraZenecaFarxiga$864$28,77629 claims
AbbVieLinzess, Synthroid$579$25,51967 claims
Sumitomo Pharma America, Inc.Gemtesa$74$15,47223 claims
MerckBelsomra$301$4,90711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,332 family providers in Virginia.

Other family in Abingdon

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →